China Biotech: Read-Through from Opdivo/Keytruda's Recent Failures (Liver Cancer & Gastric Cancer)
BMS recently reported failed Phase III clinical trial for Opdivo, one of two leading anti-PD-1 (programmed cell death protein 1) monoclonal...
425 Views
Junshi Bioscience Lock-Up Expiry: Valuation Still Rich with Few R&D Updates
Shanghai Junshi Bioscience Co. Ltd. (1877 HK) was listed on December 2018 and recorded a stellar debut performance thanks to the NDA approval for...
427 Views
Shanghai Henlius (复宏汉霖) IPO: Valuation of Four Biosimilars
Shanghai Henlius, a clinical-stage pharmaceutical company back by Fosun Pharma, is seeking a listing in Hong Kong. In our previous insight, we have...
894 Views
Mabpharm IPO Preview: Mixed Prospects of Phase 3 Drug Candidates
MabPharm (2181 HK) is a pre-revenue biopharmaceutical company in China with a focus on drugs and biosimilars for cancers and autoimmune diseases....
584 Views
ECM Weekly (18 April 2019) - Duiba Group, MabPharm, Huami, Cofco Meat, Innovent, Times China
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
868 Views